These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 10231151)

  • 21. Prevention of veno-occlusive disease with defibrotide after allogeneic stem cell transplantation.
    Chalandon Y; Roosnek E; Mermillod B; Newton A; Ozsahin H; Wacker P; Helg C; Chapuis B
    Biol Blood Marrow Transplant; 2004 May; 10(5):347-54. PubMed ID: 15111934
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Recombinant tissue plasminogen activator (rTPA) for hepatic veno-occlusive disease after allogeneic BMT in a pediatric patient.
    Feldman L; Gabai E; Milovic V; Jaimovich G
    Bone Marrow Transplant; 1995 Nov; 16(5):727. PubMed ID: 8547875
    [No Abstract]   [Full Text] [Related]  

  • 23. Treatment of sinusoidal obstruction syndrome with defibrotide: a single-center experience.
    Sucak GT; Aki ZS; Yagcí M; Yegin ZA; Ozkurt ZN; Haznedar R
    Transplant Proc; 2007 Jun; 39(5):1558-63. PubMed ID: 17580188
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Treatment of hepatic veno-occlusive disease after bone marrow transplantation with recombinant human tissue plasminogen activator (rh-tPA)].
    Yoshimi A; Kato K; Maeda N; Matsuyama T; Kojima S
    Rinsho Ketsueki; 2000 Feb; 41(2):103-8. PubMed ID: 10723238
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Successful treatment of an infant with veno-occlusive disease developed after allogeneic bone marrow transplantation by tissue plasminogen activator, heparin and prostaglandin E1.
    Higashigawa M; Watanabe M; Nishihara H; Tabata N; Azuma E; Ido M; Ito M; Sakurai M
    Leuk Res; 1995 Jul; 19(7):477-80. PubMed ID: 7637394
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Use of defibrotide in the treatment and prevention of veno-occlusive disease.
    Richardson P; Linden E; Revta C; Ho V
    Expert Rev Hematol; 2009 Aug; 2(4):365-76. PubMed ID: 21082942
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tissue plasminogen activator (tPA) as therapy for hepatotoxicity following bone marrow transplantation.
    Schriber J; Milk B; Shaw D; Christiansen N; Baer M; Slack J; Tezcan H; Wetzler M; Herzig G
    Bone Marrow Transplant; 1999 Dec; 24(12):1311-4. PubMed ID: 10627640
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Veno-occlusive disease in pediatric patients affected by Wilms tumor.
    Cesaro S; Spiller M; Sartori MT; Alaggio R; Peruzzo M; Saggiorato G; Bisogno G
    Pediatr Blood Cancer; 2011 Aug; 57(2):258-61. PubMed ID: 21246705
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: review and update on the use of defibrotide.
    Ho VT; Linden E; Revta C; Richardson PG
    Semin Thromb Hemost; 2007 Jun; 33(4):373-88. PubMed ID: 17525895
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The use of defibrotide in blood and marrow transplantation.
    Richardson PG; Carreras E; Iacobelli M; Nejadnik B
    Blood Adv; 2018 Jun; 2(12):1495-1509. PubMed ID: 29945939
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Complete resolution of transplantation-associated thrombotic microangiopathy and hepatic veno-occlusive disease by defibrotide and plasma exchange.
    Beşişik SK; Oztürk GB; Calişkan Y; Sargin D
    Turk J Gastroenterol; 2005 Mar; 16(1):34-7. PubMed ID: 16252186
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Defibrotide for hepatic VOD in children: exact statistics can help!
    Ammann RA
    Bone Marrow Transplant; 2004 Aug; 34(3):277-8. PubMed ID: 15170162
    [No Abstract]   [Full Text] [Related]  

  • 33. Recombinant human tissue plasminogen activator for the treatment of severe hepatic veno-occlusive disease in pediatric bone marrow transplant patients.
    Leahey AM; Bunin NJ
    Bone Marrow Transplant; 1996 Jun; 17(6):1101-4. PubMed ID: 8807121
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Recombinant human tissue plasminogen activator without heparin is effective in the treatment of hepatic veno-occlusive disease.
    Gherlinzoni F; Vianelli N; Valdrè L; Catani L; Tani M; Tura S
    Haematologica; 1999 Feb; 84(2):191-2. PubMed ID: 10091426
    [No Abstract]   [Full Text] [Related]  

  • 35. Hepatic veno-occlusive disease in pediatric stem cell transplantation: impact of pre-emptive antithrombin III replacement and combined antithrombin III/defibrotide therapy.
    Haussmann U; Fischer J; Eber S; Scherer F; Seger R; Gungor T
    Haematologica; 2006 Jun; 91(6):795-800. PubMed ID: 16769582
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase II trial of heparin prophylaxis for veno-occlusive disease of the liver in children undergoing bone marrow transplantation.
    Rosenthal J; Sender L; Secola R; Killen R; Millerick M; Murphy L; Cairo MS
    Bone Marrow Transplant; 1996 Jul; 18(1):185-91. PubMed ID: 8832013
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Defibrotide for Sinusoidal Obstruction Syndrome/Veno-Occlusive Disease Prophylaxis in High-Risk Adult Patients: A Single-Center Experience Study.
    Picod A; Bonnin A; Battipaglia G; Giannotti F; Ruggeri A; Brissot E; Malard F; Médiavilla C; Belhocine R; Vekhoff A; Gueye MS; Lapusan S; Adaeva R; Isnard F; Legrand O; Baylatry MT; Joly AC; Labopin M; Duléry R; Mohty M
    Biol Blood Marrow Transplant; 2018 Jul; 24(7):1471-1475. PubMed ID: 29477779
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The fibrinolytic mechanism of defibrotide: effect of defibrotide on plasmin activity.
    Echart CL; Graziadio B; Somaini S; Ferro LI; Richardson PG; Fareed J; Iacobelli M
    Blood Coagul Fibrinolysis; 2009 Dec; 20(8):627-34. PubMed ID: 19809307
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost-Effectiveness of Defibrotide in the Prophylaxis of Veno-Occlusive Disease after Pediatric Allogeneic Stem Cell Transplantation.
    Pichler H; Horner K; Engstler G; Poetschger U; Glogova E; Karlhuber S; Martin M; Eibler W; Witt V; Holter W; Matthes-Martin S
    Biol Blood Marrow Transplant; 2017 Jul; 23(7):1128-1133. PubMed ID: 28359910
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Color-flow imaging sonography of portal and hepatic vein flow to monitor fibrinolytic therapy with r-TPA for veno-occlusive disease following myeloablative treatment.
    Sonneveld P; Laméris JS; Cornelissen J; Ogilvie A; Löwenberg B
    Bone Marrow Transplant; 1998 Apr; 21(7):731-4. PubMed ID: 9578316
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.